Ethical and Legal Considerations
- 65 Downloads
In this chapter, the four basic principles of biomedical ethics are discussed in relation to clinical decision-making for patients with SUDs and their families: (1) beneficence, (2) non-maleficence, (3) respect for autonomy and (4) justice. Examples focusing on decisions particular to medication treatment for OUD are presented. Stigma is considered. Additionally, some of the regulatory frameworks that affect substance use are reviewed, including current laws to expand access and availability of naloxone for opioid overdose reversal, the Harrison Narcotics Tax Act of 1914 and the Controlled Substances Act of 1970. The Narcotic Addict Treatment Act of 1974 and the Drug Addiction Treatment Act of 2000 (DATA 2000), under which opioid agonist treatments have been delivered in the United States are explored. Patient confidentiality laws such as 42 CFR Part 2 are also examined.
KeywordsBeneficence Non-maleficence Respect for autonomy Justice Harrison Narcotic Act of 1914 Drug Addiction Treatment Act (DATA) 2000 CFR 42 Part 2 Stigma
- 1.Beauchamp TL, Childress JF. Principles of biomedical ethics. 7th. ed. New York: Oxford University Press; 2012.Google Scholar
- 4.U.S. Department of Health and Human Services. Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment Improvement Protocol (TIP) series 43. DHHS publication no. (SMA) 05-4048. Substance Abuse and Mental Health Services Administration: Rockville; 2005.Google Scholar
- 6.American Association for the Treatment of Opioid Dependence (AATOD). Canon of Ethics [Internet]. AATOD. 2019. [cited 2019 May 10]. Available from: http://www.aatod.org/member-center/canon-of-ethics/.
- 16.Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths – United States, 2013–2017. Morb Mortal Wkly Rep. 2019;67(5152):1419–27.Google Scholar
- 17.U.S. Department of Health and Human Services. HHS acting secretary declares public health emergency to address national opioid crisis. 2017. [cited 2019 May 10]. Available from: https://www.hhs.gov/sites/default/files/opioid%20PHE%20Declaration-no-sig.pdf.
- 19.National Institute of Law Enforcement and Criminal Justice. The Nation’s toughest drug law: evaluating the New York experience – final report of the Joint Committee on New York Drug Law Evaluation. New York: The Association of the Bar of the City of New York; 1978.Google Scholar
- 20.Kaeble D, Cowhig M. Correctional populations in the United States, 2016. U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. 2018; NCJ 251211:1–13. [cited 2019 May 10]. Available from: https://www.bjs.gov/content/pub/pdf/cpus16.pdf.
- 21.Kaiser Family Foundation. Status of state action on the medicaid expansion decision [Internet]. KFF State Health Facts. 2018. [cited 2019 May 10]. Available from: https://www.kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act.
- 24.Network for Public Health Law. Legal interventions to reduce overdose mortality: naloxone access and overdose good Samaritan Laws. Network for Public Health Law (USA); 2018 [cited May 10, 2019]. Available from: https://www.networkforphl.org/_asset/qz5pvn/legal-interventions-to-reduce-overdose.pdf.
- 25.Harrison Narcotics Tax Act. Public law # 63–223. 1914.Google Scholar
- 26.Webb v. United States, 249 U.S. 96, 39 S. Ct. 217, 63 L. Ed. 497. 1919.Google Scholar
- 27.Linder v. United States, 268 U.S. 5, 45 S. Ct. 446, 69 L. Ed. 819. 1925.Google Scholar
- 28.U.S. Food and Drug Administration. Methadone oral concentrate (methadone hydrochloride oral concentrate USP) and methadone sugar- free oral concentrate (methadone hydrochloride oral concentrate USP) dye-free, sugar-free, unflavored. [cited 2019 May 10]. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017116s021lbl.pdf.
- 29.Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction. Proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. 42 C.F.R. § 8.12 (2016) [regulation on the Internet]. [cited 2019 May 10]. Available from: https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=e3d2eafa3a0991f90e93a038912a687e&mc=true&n=pt42.1.8&r=PART&ty=HTML#sp42.1.8.c.
- 30.U.S. Department of Health and Human Services. Qualify for a practitioner waiver [Internet]. Substance Abuse and Mental Health Services Administration. 2019. Available from: https://www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management/qualify-for-practitioner-waiver.
- 31.CSAT (Center for Substance Abuse Treatment). The confidentiality of alcohol and drug abuse patient records regulation and the HIPAA privacy rule: implications for alcohol and substance abuse programs. DHHS publication no. (SMA) 04-3947. Substance Abuse and Mental Health Services Administration: Rockville; 2004. https://www.integration.samhsa.gov/operations-administration/the_confidentiality_of_alcohol_and_drug_abuse.pdf.Google Scholar